SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

"What's Updog?" is a Community Led token.

UpDog

$UPDOG.X is trending as the community rallies around the long-standing joke and the coin's presence on the Solana network. Community members are actively engaging in the 'What's UpDog?' meme, celebrating its resilience and unique place as the only UPDOG on the Jupiter Strict List.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as the community discusses potential revenue generation and real-world asset (RWA) adoption. Some users are speculating on partnerships and integrations with other projects. Bullish sentiment is fueled by discussions of on-chain matrix rewards and treasury mechanics.

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

$BYTE.X is trending as an AI meme coin linked to Elon Musk's Grok, sparking community excitement. The "Byte Army" is actively promoting the token, emphasizing its community-owned nature and potential in the AI and meme coin sectors. Discussions also highlight whale accumulation and positive sentiment from LunarCrush.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors discuss its partnerships with major tech companies like AMD and Nvidia, particularly regarding QNX's role in automotive and robotics. Community members are highlighting the company's potential for growth and a possible breakout, fueled by anticipation for upcoming earnings. The conversation also includes discussions around technical analysis, market manipulation, and BlackBerry's long-term prospects as a software and cybersecurity player.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending due to its recent listing on Bifinance, generating excitement about increased liquidity and exposure. The community emphasizes its consistent 'grind,' utility development, and active developer, setting it apart from other meme coins. Many express bullish sentiment and highlight the project's commitment to delivering on promises, with some mentioning an upcoming burn event.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Enthusiastic community members are actively promoting $CAW.X, a memecoin known as "crow with knife", across various chains. The community emphasizes its deflationary nature and strong social presence, encouraging others to join and "caw caw" their way to potential gains. Mentions of "layer zero burn mechanism in place" and "crow with knife is the only option" highlight key community talking points.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MLTX is trending due to positive Phase 2 trial results for their drug, sonelokimab, in treating hidradenitis suppurativa, leading to community excitement about its potential. The community is discussing the implications of the data and speculating on a potential buyout, with some analysts increasing price targets. However, there is also caution regarding potential dilution from a public offering and debate about the company's data disclosures.

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Resmed Inc.

ResMed ($RMD) is trending due to speculation around a potential partnership or acquisition with Incannex ($IXHL), fueled by positive Phase 2 results for Incannex's sleep apnea pill and a ResMed advisor on Incannex's clinical advisory board. Community members are discussing the strategic implications of a potential deal, with some suggesting it could revolutionize sleep apnea treatment. The community highlights the potential for a significant market impact should Incannex and ResMed collaborate.

The centrifuge token model powers centrifuge, providing the framework needed to run the platform without reliance on a single point of failure, including the centrifuge team or Company, and to accelerate its utility. To accomplish this, centrifuge leverages the cryptoeconomic primitives of a native token called the centrifuge token (cfg), a nominated-proof-of-stake consensus algorithm that employs centrifuge to stake value, rewards for centrifuge adoption, and an on-chain governance mechanism that empowers centrifuge holders to guide the development of centrifuge.

Centrifuge

Centrifuge ($CFG.X) is gaining attention, fueled by its focus on Real World Assets (RWAs) and recent integrations that facilitate easier tokenization and DeFi utilization. Community members highlight its potential to bridge traditional finance with DeFi, pointing to partnerships and new asset onboarding processes as catalysts. Discussions also revolve around technical analysis, potential price targets, and the impact of broader market trends.

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals is trending due to anticipation surrounding upcoming Phase 2b RSV drug results, sparking community discussion about its potential impact. Some are focused on technical levels to watch for momentum, while others are considering potential long-term gains. The broader context involves Enanta's pipeline and potential in the antiviral market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer

SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...

Oncternal Therapeutics (NASDAQ:ONCT) Upgraded by StockNews.com to "Hold"

StockNews.com upgraded shares of Oncternal Therapeutics (NASDAQ:ONCT  Free Report) from a sell rating to a hold rating in a research report released on Friday morning.
A number of other...

Analysts Offer Insights on Healthcare Companies: Joint (JYNT), Xtant Medical Holdings (XTNT) and Oncternal Therapeutics (ONCT)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Joint (JYNT Research Report), Xtant Medical Holdings...

Oncternal Therapeutics reports Q4 EPS ($3.11), consensus (3.07)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

Third dosing cohort fully enrolled for our Phase 1/2 study for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are resistant to...

Panorama des b n fices de Oncternal Therapeutics

Oncternal Therapeutics (NASDAQ:ONCT) publiera ses derniers b n fices ce jeudi, 7 mars. Pour en savoir plus ce sujet, veuillez consulter ce guide aux b n fices du quatri me trimestre publi s...

Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results

SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...

Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference

SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...

Oncternal Therapeutics reports inducement award under Nasdaq listing rule

Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...

Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.

Oncternal Therapeutics Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

Current Price	$0.5266
Prev Close	$0.6939
Open	$0.70
Dividend Yield	N/A
50-Day Moving Average	$0.5266
Beta	0.41
Avg. Volume	0.00
PE Ratio	-0.05

52-Week High	$2.37
52-Week Low	$0.5266
Market Capitalization	$1.56M
EPS (Annual)	N/A
Price to Book	0.17
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

ONCT
Oncternal Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ONCT News

ONCT Oncternal Therapeutics Inc